March 3, 2021 |
Biomedical Engineering
Using nanoparticles to deliver drugs directly to tumors is a novel technology developed by NanoMedTrix, LLC, a UI spin-off founded by Jose Assouline, an adjunct associate professor in the Roy J. Carver Department of Biomedical Engineering and the Roy J. and Lucille A. Carver College of Medicine. The targeted delivery of these nanoparticles to treat diseases such as bladder cancer has led to a two-year, $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute.
“Not only do these nanoparticles bind to tumors for treatment, but they also provide imaging of the tumors which we can then analyze,” said Assouline. “These valuable images computed remotely, which has appreciable clinical usefulness during the pandemic when we are working to limit close-contact interactions.”